908 Devices supplies rugged handheld analyzers that integrate high‑pressure mass spectrometry, FTIR and Raman spectroscopy to identify thousands of chemicals, explosives, narcotics and gases at trace levels in solids, liquids, aerosols and vapors. The instruments deliver results in seconds via on‑device AI libraries and support Bluetooth/Wi‑Fi data transfer to mobile or cloud platforms, with interchangeable sampling modules for multiple threat categories. They target first‑responders, law‑enforcement, customs and defense teams needing rapid, on‑site chemical threat assessment.

Accompany Health provides integrated in-home and mobile care services encompassing medical, mental health, and social support. Their multidisciplinary team coordinates patient needs, attends external appointments, and assists with social determinants of health like housing and food access. These comprehensive services are generally covered by insurance, offering patients convenient, personalized healthcare outside traditional clinic settings.

Aera Therapeutics utilizes a protein nanoparticle (PNP) delivery platform that self-assembles from endogenous human proteins to package and transfer nucleic acid cargo. This technology addresses the limitations of current delivery methods for genetic medicines, enabling broader therapeutic applications.

The company develops oral, enzyme‑targeted small‑molecule therapies that enhance glycolytic flux in red blood cells to increase ATP production and reduce hemolysis in rare hemolytic anemias such as pyruvate kinase deficiency, thalassemia, and sickle cell disease. Its platform combines structure‑based drug design, biomarker‑driven adaptive trials, and companion diagnostics to deliver disease‑modifying effects and support precision enrollment for hematologists and specialty clinics. Partnerships with pharmaceutical firms and academic centers accelerate development and broaden access to these metabolic treatments.

AIRNA is developing RNA editing therapies to treat rare and common diseases by precisely modifying RNA sequences to correct genetic mutations. This approach aims to enhance patient health outcomes by targeting the underlying causes of genetic disorders.

Akamis Bio is a clinical-stage oncology company focused on developing targeted therapies for cancer treatment. Their approach utilizes precision medicine to enhance treatment efficacy and minimize side effects for patients with specific tumor profiles.

Aledade operates the largest network of independent primary care through its Accountable Care Organizations (ACOs), utilizing data analytics and guided workflows to enhance patient outcomes and financial sustainability for practices. By facilitating value-based care, Aledade enables over 1,900 practices to improve care coordination and achieve shared savings, impacting more than 2.5 million patients across the U.S.

Alnylam develops RNA interference medicines that silence disease‑causing genes using chemically modified siRNAs delivered via proprietary platforms such as GalNAc conjugates for liver targeting and lipid nanoparticles for systemic use. Its portfolio includes FDA‑approved treatments for rare genetic and protein‑misfolding disorders and a pipeline of additional indications, with revenue from product sales, technology licensing, and patient‑support services.

Altos Labs utilizes cellular rejuvenation programming to restore cellular health and resilience, targeting the underlying mechanisms of disease and injury. By enhancing the ability of cells to resist stressors, the company aims to improve overall health and mitigate age-related disabilities.

Develops proprietary genomic editors that target the root causes of genetic diseases by selecting optimal editing tools based on disease-specific pathology. This approach enables the discovery and development of potentially curative genomic medicines, with a focus on liver and central nervous system disorders.

Areteia Therapeutics is developing dexpramipexole, a first-in-class oral medication that inhibits eosinophil maturation to reduce inflammation in patients with eosinophilic asthma. This approach addresses the significant unmet need for effective treatments in a condition affecting millions globally, where current therapies often fall short.

ArsenalBio develops programmable CAR T-cell therapies specifically targeting solid tumors, utilizing a computationally driven approach to enhance treatment efficacy. The company addresses the challenge of treating cancer's complex nature by engineering cell therapies that aim to improve patient outcomes.

Aspen Neuroscience develops autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy specifically for Parkinson's disease, utilizing advanced stem cell biology and genomics. This approach addresses the degeneration of neurons in patients, aiming to restore lost function and improve quality of life.

Autobahn Therapeutics is developing orally administered small molecule prodrugs using a brain-targeting chemistry platform to create tailored therapies for neuropsychiatric and neuroimmunologic disorders. Their approach focuses on restoring brain health by leveraging validated human biology and biomarker-driven development to address the progressive nature of these debilitating conditions.

Basking Biosciences is developing BB-031, a reversible RNA aptamer designed to target von Willebrand Factor for the treatment of acute ischemic stroke. This therapy aims to provide a rapid-onset, short-acting solution for reopening blocked arteries while allowing for quick neutralization in case of bleeding complications.

Beam Therapeutics develops precision genetic medicines using base editing technology to enable targeted modifications of DNA sequences. This approach addresses the limitations of traditional gene editing methods, offering potential treatments for genetic disorders with improved accuracy and reduced off-target effects.

Be Biopharma is developing engineered B cell therapies to treat serious diseases, focusing on conditions like hemophilia B. Their approach utilizes protein-based treatments to enhance patient outcomes and improve quality of life for those affected.

Bit.bio develops a cell coding platform that utilizes deterministic programming to create and manufacture any human cell type with precision and scalability. This technology addresses the need for consistent and reliable cell production for research and therapeutic applications, enabling the development of next-generation treatments.

Bitterroot Bio is developing anti-CD47 immunotherapies to target the inflammatory processes underlying atherosclerosis, a major contributor to cardiovascular disease. By enhancing macrophage activity to reduce plaque formation, the company aims to decrease the incidence of heart attacks and strokes.

Bitterroot Bio develops anti-CD47 immunotherapies to target the inflammatory processes underlying atherosclerosis, a major contributor to cardiovascular disease. By enhancing macrophage activity, these therapies aim to reduce plaque formation and the risk of heart attacks and strokes.

The startup has developed a synthetic chemistry platform that generates novel pharmacophores and drug modalities to meet unmet therapeutic needs. Its technology enhances sustainable farming by producing a compound that minimizes fungicide resistance and reduces chemical applications while maintaining efficacy.

Boundless Bio is a precision oncology company developing ecDNA-directed therapies (ecDTx) to target oncogene amplified cancers, which affect over 5 million patients annually and currently lack effective treatment options. By leveraging their proprietary Spyglass platform, Boundless Bio identifies and exploits the vulnerabilities associated with extrachromosomal DNA, a key mechanism driving tumor growth and resistance to existing therapies.

Brii Biosciences develops first-in-class therapies utilizing RNA interference and other biotechnological methods to treat infectious diseases and central nervous system disorders. The company focuses on addressing high unmet medical needs in patient populations facing limited treatment options and social stigmas.

Carrick Therapeutics develops targeted cancer therapies that combine CDK12/13 inhibitors with existing oncology drugs to treat aggressive forms of breast, prostate, and ovarian cancers. Their approach addresses the challenge of treatment resistance in advanced cancer patients, aiming to improve clinical outcomes through innovative combination therapies.